《复牌表现》中国医疗(08225.HK)申请恢复生产对新型冠状病毒有疗效利托那韦 股价续飙1倍
中国医疗集团(08225.HK)向药监局申请恢复生产对新型冠状病毒(2019-nCoV)有抑制作用和疗效的利托那韦(Ritonavir),该股继昨天飙升2.8倍中途停牌後,今天复牌再续升势,最多续涨1.2倍至0.95元,接近2015年5月所创上市高位1.01元遇阻,现造0.87元,续涨1倍,成交续增至2.37亿股,为数年来罕见,涉资1.65亿元。
中国医疗公布,旗下新型冠状病毒肺炎临床特别专案组研究发现利托那韦(Ritonavir)对新型冠状病毒(2019-nCoV)有抑制作用和疗效报告,中国科学院武汉病毒研究所等也发现其在细胞层面上对新型冠状病毒(2019-nCoV)有较好抑制作用。目前集团关联公司万全万特厦门是一家唯一国内历史生产过该产品制剂,企业同时拥有原料批文,申请相关专利和已经向国家药监局申请重新恢复生产,集团将负责进一步临床研究和申报工作。除此之外,公司董事局确认不悉任何导致昨天股价及成交量异常变动之因。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.